Gemcitabine is a cytidine analogue which was hailed as a futuristic anticancer drug when it was first approved for pancreatic cancer towards the end of the 20th century.

Gemcitabine is a cytidine analogue which was hailed as a futuristic anticancer drug when it was first approved for pancreatic cancer towards the end of the 20th century. Since then it has been one of the most well researched molecule which provided valuable options in patients who were refractory or resistant to first-line treatment in certain advanced cancers or were unable to use certain drugs for reaching the maximum cumulative dose in earlier protocols.

Indications:

  • Ovarian Cancer – For the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy gemcitabine in combination with carboplatin is indicated
  • Breast Cancer – GEMGET in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated

 

  • Non-Small Cell Lung Cancer – GEMGET is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer

 

  • Pancreatic Cancer – GEMGET is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas

 

  • GEMGET is indicated for patients previously treated with 5-FU

 

Generic Name Strength Standard Type Packing Pack Size
Gemcitabine 200 mg USP INJ Vial  Vial
Gemcitabine 1 g USP INJ Vial  Vial